Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
Provided By GlobeNewswire
Last update: Mar 18, 2025
SAN FRANCISCO, March 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the fourth quarter and full year ended December 31, 2024.
Read more at globenewswire.com
